AGG Talks: Government Insight for Life Sciences Leaders Podcast Series
Our podcast series hosts strategic conversations at the center of life sciences, law, and policy. During each episode, AGG’s former government attorneys bring firsthand knowledge and updates from their respective agencies — such as the HHS and DOJ — and examine how the latest regulatory developments and enforcement trends impact life sciences organizations. These insider insights, paired with the practical experience of AGG’s Life Sciences team, offer the life sciences industry a map of the road ahead in today’s regulatory environment.
AGG Talks: Government Insight for Life Sciences Leaders Podcast Series
DOJ’s Shifting Enforcement: CPB Disbanding, Counterfeit Drug Focus, and Gender-Affirming Care Investigations
In this episode, Alan Minsk, AGG Food & Drug practice chair and Life Sciences co-chair, and Gabe Scannapieco, Litigation and Healthcare partner and Life Sciences co-chair, unpack recent shifts at the U.S. Department of Justice that could reshape regulatory risk for life sciences organizations.
They discuss the disbanding of DOJ’s Consumer Protection Branch ("CPB") and what the loss of centralized oversight could mean for coordinated investigations in the industry. The conversation also examines DOJ’s intensified focus on counterfeit drugs and its targeting of the entire supply chain in collaboration with FDA, DEA, and other agencies.
Drawing on Gabe’s experience as a former assistant director at the CPB and the firm's extensive regulatory services, this episode provides practical insights for companies looking to stay ahead of shifting enforcement priorities.